Showing results (331-340 of 385) with videos related to

Sort By:
Pageof 39
Bioorganic Chemistry|October 4, 2019
Novel inhibitors of leukocyte transendothelial migrationTamar Getter, Raanan Margalit, Shirin Kahremany, et al.
Molecular Therapy. Methods & Clinical Development|May 4, 2022
Gene therapy for guanidinoacetate methyltransferase deficiency restores cerebral and myocardial creatine while resolving behavioral abnormalitiesSuhail Khoja, Jenna Lambert, Matthew Nitzahn, et al.
Lancet (London, England)|June 5, 2009
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trialNubia Muñoz, Ricardo Manalastas, Punee Pitisuttithum, et al.
Gastroenterology|October 11, 2016
Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C InfectionPaul Kwo, Edward J Gane, Cheng-Yuan Peng, et al.
Atherosclerosis|January 21, 2017
Molecular genetics of familial hypercholesterolemia in Israel-revisitedRonen Durst, Uche Ken Ibe, Shoshi Shpitzen, et al.
Hepatology (Baltimore, Md.)|March 4, 2017
Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III StudyChristophe Hézode, Massimo Colombo, Marc Bourlière, et al.
Vaccine|July 13, 2004
Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy womenKenneth H Fife, Cosette M Wheeler, Laura A Koutsky, et al.
Clinical and Vaccine Immunology : CVI|April 13, 2007
Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccinesSuzanne M Garland, Marc Steben, Mauricio Hernandez-Avila, et al.
Journal of Viral Hepatitis|May 21, 2019
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6Eric Lawitz, Edward Gane, Jordan J Feld, et al.
Lancet (London, England)|October 13, 2015
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 studyDavid Roth, David R Nelson, Annette Bruchfeld, et al.
Pageof 39